替吉奥同步化疗联合放疗治疗老年食管癌的临床疗效分析

目的观察替吉奥同步化疗联合放疗治疗老年食管癌的临床疗效及不良反应。方法回顾性分析老年食管癌病人70例临床资料，其中接受单纯放疗和同步化疗病人各35例。2组均全程采用三维适形调强放疗，同步化疗组同时采用替吉奥胶囊单药化疗。按照实体瘤评价标准（完全缓解、部分缓解、疾病稳定和疾病进展）评价近期疗效，并采用NCI-CTC对不良反应进行评定。随访2年，比较2组的中位生存时间和总生存率。结果同步化疗组治疗总有效率为85.71%（30/35），高于单纯放疗组的60.0%（21/35）（χ2=5.85，P < 0.05）。2组均未出现因不良反应致死或终止治疗的病人，病人均能较好耐受，2组Ⅲ~Ⅳ级骨髓抑制及放射性食管炎发生率差异均无统计学意义（P>0.05）。随访2年，同步化疗组和单纯放疗组分别有1例和3例病人失访，同步化疗组中位生存时间和2年生存率分别为24.0个月和73.53%（25/34），均高于单纯放疗组的18.0个月和46.88%（15/32）（P < 0.05）。结论替吉奥同步化疗联合放疗治疗老年食管癌近期疗效较好，不良反应较小，可提高老年病人生存率。

Clinical effect analysis of tegafur/gimeracil/oteracil concurrent chemotherapy combined with radiotherapy in the treatment of esophageal cancer in elderly patient

ObjectiveTo observe the clinical efficacy and side effects of tegafur/gimeracil/oteracil concurrent chemotherapy combined with radiotherapy in the treatment of esophageal cancer in elderly patient.MethodsThe clinical data of elderly patients with esophageal cancer were retrospectively analyzed, which included 35 patients treated with radiotherapy alone and 35 cases treated with concurrent chemotherapy.The two groups were treated with three-dimensional conformal intensity modulated radiotherapy.The concurrent chemotherapy group was additionally treated with single agent chemotherapy with tegafur/gimeracil/oteracil.The short-term efficacy was evaluated according to the criteria for evaluating solid tumors (complete remission, partial remission, disease stability and disease progression), and the side effects were evaluated using NCI-CTC.The two groups were followed up for 2 years, the median overall survival time and overall survival rate were compared between two groups.ResultsThe total effective rate in concurrent chemotherapy group (85.71%) was higher than that in chemotherapy alone group (60.0%) (P < 0.05).Two groups did not appear because of the adverse reactions to death or termination of the treatment of patients, patients could tolerate, and the differences of the incidence rates of grade Ⅲ ~ Ⅳ bone marrow suppression and radiation esophagitis between two groups were not statistically significant (P>0.05).During two years of following up, one case in concurrent chemotherapy and 3 cases in chemotherapy alone group losed to follow up.The time of median survival time and 2-year survival rate in concurrent chemotherapy group (24 months and 73.53%) were higher than those in chemotherapy alone group (18 months and 46.88%), respectively (P < 0.05).ConclusionsThe tegafur/gimeracil/oteracil concurrent chemotherapy combined with radiotherapy in the treatment of esophageal cancer in elderly patient has good short-term effects and less side effects, which can significantly improve the overall survival rate of elderly patients.